Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Clin Cancer Res. 2020 Nov 10;27(3):799–806. doi: 10.1158/1078-0432.CCR-20-2861

Figure 1. Landscape of MET exon 14-alterations in lung cancer and sequencing by RNA-based anchored multiple PCR.

Figure 1.

For many patients, the likelihood of exon 14 being skipped in their cancer based on DNA-based sequencing was high (light-green). The rest of the cases were nominated for RNA-based confirmation via the MSK-Fusion panel. In patients, with sufficient tissue for MSK-Fusion testing, cases where exon 14 skipping was confirmed are shown in dark green, while those where exon 14 skipping was not observed in RNA are shown in red. Of note, one mutation not confirmed by RNA (c.3028+1221G > A) is deep into intron 14 and is not shown. Patients whose cancers were nominated for MSK-Fusion testing but did not have sufficient tissue for test completion are shown in gray. +, 2 patients; *, 3 patients.